Objectives-As auranofin resembles some neutrophil activating sulphur containing compounds, it was decided to investigate whether it had activating effects on neutrophil migration in addition to the published inhibitory effects. Methods-The Boyden chamber assay was used to determine the migration velocity of human neutrophils. The difference between chemotaxis and chemokinesis was established with a chequerboard assay. Results-Low concentrations of auranofin stimulated human neutrophil migration; concentrations of auranofin higher than 1 gLmol/l were inhibitory. Inhibitors of leukotriene formation, or of protein kinase C, had the same effect on auranofin induced potentiation of migration as on fMLP activated migration. Auranofin, at a concentration of 100 nmolIl, caused a transient increase in the cGMP level of neutrophils. The auranofin induced increase in migration was strongly inhibited by methylene blue and by LY83583, two inhibitors of cGMP accumulation. Conclusions-The auranofin induced enhancement of migration is partly due to a chemokinetic effect, but mainly due to a chemotactic effect. The potentiating effect of auranofin on migration is not specifically due to the ability of the drug to inhibit protein kinase C activity or to generate leukotrienes. These results suggest that the enhancement of neutrophil migration by low levels of auranofin is related to the enhancement of cGMP levels in neutrophils.
The effect of auranofin on neutrophil chemotaxis has been studied by several workers. ' The drug inhibits neutrophil chemotaxis in the micromolar concentration range. In vivo studies showed an inhibition of neutrophil chemotaxis of patients receiving auranofin;' in some studies, however, a potentiation of chemotaxis was found.
A number of other functions of the stimulated neutrophil are inhibited by auranofin. These include aggregation, phagocytosis, the release of lysosomal enzymes and leukotrienes, and the respiratory burst.6-'0 Auranofin inhibits some cellular processes which might be related to inhibition of the functions. Protein kinase C activity, and the associated protein phosphorylation, are inhibited by auranofin. " 12 The drug inhibits the number of microtubules in resting neutrophils and decreases the surface charge and membrane potential of these cells. '3 A number of studies have shown that auranofin is not only inhibitory but is also able to potentiate some functions and processes in the neutrophil and in other cell types. Although micromolar concentrations of auranofin inhibited the effect of phorbol myristate acetate, lower concentrations enhanced phorbol myristate acetate induced superoxide production.9 Low concentrations of auranofin stimulated interleukin 2 production, whereas high concentrations were inhibitory.'4 Synthesis of leukotrienes was enhanced by low concentrations of auranofin.'5 Auranofin may apparently show activating and inhibitory effects, depending on the conditions. It has been found that a number of sulphur containing disease modifying drugs have a potentiating effect on migration and exocytosis by neutrophils. 1'18 As there are some similarities between these compounds and auranofin, we decided to investigate whether auranofin has activating effects on neutrophil migration in addition to the published inhibitory effects.
Materials and methods

ISOLATION OF NEUTROPHILS
Human neutrophils were isolated from the venous blood of healthy volunteers using dextran sedimentation followed by centrifugation over Ficoll-Isopaque and hypotonic haemolysis of contaminating erythrocytes. Isolated neutrophils were resuspended in a medium containing 140 mmol/l NaCl, 5 mmol/ KC1, 10 
fMLP= 1 x 10-9 mol/l fMet-Leu-Phe, present in the lower compartment of the Boyden chamber.
means (SEM), calculated on the basis of all 15 determinations. The significance was calculated with Student's t test; p<0 01 was considered as statistically significant.
Results
Random migration by neutrophils was stimulated if auranofin was present in the lower compartment of the Boyden chamber in the concentration range up to 1 pumol/l (fig 1) .
Maximum stimulation occurred at a concentration of 0-1 p.mol/l auranofin. Concentrations of auranofin higher than 1 pmol/l inhibited random locomotion. The effect of auranofin strongly depended on the location of the drug with respect to the cells, and whether or not a chemotactic agent was present (table 1). The activating effect was strong when auranofin (1 X 10 mol/l) was present in the lower compartment only. When the drug was present in the two compartments the effect was moderate, and the effect was small when auranofin was present in the upper compartment with the cells.
The effect of auranofin on fMLP induced chemotaxis was tested. Auranofin (10' mol/l) had little effect when the chemotactic agent fMLP was present in the lower compartment.
A concentration of 20 p.mol/l auranofin was inhibitory, not only on random migration but especially on fMLP induced chemotaxis; the effect was most pronounced when the drug was present in the two compartments of the Boyden chamber (table 1) . A chequerboard assay was carried out to establish the relative contributions of chemokinesis and chemotaxis in auranofin stimulated neutrophil migration. Migration was higher than calculated on the basis of chemokinesis alone when the concentration of auranofin in the lower compartment was higher than in the upper compartment. The reverse was true when the concentration below the filter was lower than in the upper compartment (table 2) .
To determine the possible involvement of leukotriene B4 in auranofin induced enhancement of migration, several inhibitors of leukotriene formation were tested. These inhibitors (naproxen, felodipine, nordihydroguaiaretic acid, and quercetin) were tested in concentrations which are known to inhibit strongly leukotriene formation.2' As a control the effect of these inhibitors on fMLP induced migration was tested. Inhibition of auranofin induced migration was about the same as that of fMLP induced migration (table 3). As auranofin affects protein kinase C mediated neutrophil functions the same procedure was followed to determine a role for protein kinase C Effect of auranofin on neutrophil migration (1 xl-9 mol/l) were present in the lower compartment only. Migration in the absence of activating agent was 43-8 (1-7) ,um.
maximum effect was observed after the incubation of neutrophils for about five minutes with auranofin ( fig 2) . Methylene blue, an inhibitor of cGMP accumulation, had little effect on random migration, but inhibited the enhancement of migration induced by a low concentration of auranofin. The inhibitory effect of a higher concentration of auranofin on fMLP induced migration was not decreased by methylene blue (table 4) . LY83583, an inhibitor of guanylate cyclase, gave the same effects as methylene blue; the inhibitory effects were even more pronounced (table 4) . Methylene blue and LY83583 were tested to see whether they inhibited auranofin induced cGMP The activating agents (1 x O1 mol/l auranofin, 1 X O1 molA fMLP) were only present in the lower compartment of the Boyden chamber; methylene blue, LY83583, and the inhibitory concentration of auranofin (2x 10-5 moLI) were present in the two compartments.
accumulation in neutrophils under the conditions of our experiments. Although auranofin (1xX 10`molIl, incubation time five minutes) gave an increase of cGMP from 2.5 (0.2) to (1.6) pmol/107 cells, the increase was reduced to 1 9 (04) pmol/107 cells in the presence of methylene blue, and to 2-3 (0 3) pmol/107 cells in the presence of LY83583. The inhibitors had little effect on the cGMP level of resting cells.
Discussion
The results presented here show that auranofin not only has inhibitory effects on migration, but that at low concentrations the drug stimulates neutrophil migration. The stimulating effect is partly chemokinetic because migration is enhanced when auranofin is present in the upper and lower compartments of the Boyden chamber. The strongest enhancement of migration is observed when the drug is present in the lower compartment only, indicating that auranofin also has chemotactic properties. The relative contribution of chemokinesis and chemotaxis in the activating effect of auranofin on neutrophil migration can be derived from the chequerboard assay.23 This shows that chemotaxis and chemokinesis contribute to the enhancing effect on neutrophil migration. The chemotactic component, however, is stronger than the chemokinetic component.
At low concentrations auranofin stimulates leukotriene B4 generation. As this leukotriene is chemotactic it is conceivable that a relation exists between the generation of the leukotriene and the enhanced motility induced by auranofin. A series of inhibitors of leukotriene generation, however, had little effect on auranofin induced migration, and if there was a slight inhibition it was not more than for fMLP induced migration. This makes it unlikely that leukotriene formation affects the potentiating effect of auranofin on neutrophils. Protein kinase C activity is required for the synthesis of leukotriene B4 in neutrophils.24
Auranofin modulates some leucocyte functions by interacting with protein kinase C." 12 Two inhibitors of protein kinase C, in concentrations which completely inhibit the enzyme, have no more effect on auranofin induced migration than on fMLP induced migration. This suggests that the potentiating effect of auranofin on migration is not specifically mediated by protein kinase C, and supports the view that leukotrienes do not play a part in this potentiating effect.
A possible role for cGMP in neutrophil migration has been suggested. 
